Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies

The Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, has entered into a second research collaboration with Celgene that aims to create and develop high-performance recombinant antibodies against diverse targets in human cells.


Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced a partnership with the Recombinant Antibody Network (RAN), a consortium of three expert centers at the University of Chicago, University of Toronto, and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies at a proteome-wide scale.


RAN to collaborate with Celgene on cancer therapeutics development

The RAN has recently signed a 3-year $25M agreement with the Celgene Corporation to develop next-generation, antibody-based cancer therapies with the option to enter into future license agreements. Collaboration will focus on novel high value cancer targets. Besides supporting the high throughput antibody generating pipelines, this agreement will enable setting up robotics for a battery of state of the art cell based assays. The capacity that can be achieved with regard to antibody generation and target validation is unmatched by any similar facility in the world. 


'IP gold standard' antibodies for select chromatin-related human proteins developed

We have established a collection 'IP gold standard' antibodies in the tour de force study of 1,124 new recombinant antibodies for 152 chromatin-related human proteins. This set is accomapnied with a collection of SOPs which can be accesed here


852 rAbs in our catalog!

We have recently updated the antibody catalog


New binders added to antibody catalog

We have recently updated the antibody catalog with new antibody binders that are made available by the Recombinant Antibody Network. There are currently 495 binders available in the catalog.


Automated antibody phage display selection and screening system

Advanced robotic system designed to screen thousands of recombinant antibodies without human intervention. Video shows sequence of ELISA and colony picking schedules executed on the same system. Portions of this video has been speed up by a factor of 2.


UCSF RAN Node Receives QB3 funds to explore alternative protein expression platforms

In December 2012 the UCSF node of the RAN received funding from the California Instituet for Quantitative Biosciences (QB3) to kickstart the development of two automated protein expression pipelines designed to suppliment the RAN antigen needs.


RAN: A proven track record for collaboration

A major strength of the management structure is the proven record of the leadership to work in unison to manage large, complex and intellectually challenging programs. In fact, several of the team have successfully managed projects in industry that were significantly larger and more complex than what is proposed here. Further, the RAN leadership team is linked through a unique history of collaborative interaction that spans over two decades.

Subscribe to News

University of Toronto  UCSF  The University of Chicago  QB3  Chicago Biomedical Consortium